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Summary
Background: Bodybuilding supplements can cause a profound cholestatic syndrome.
Aim: To describe the drug‐Induced liver injury network's experience with liver injury
due to bodybuilding supplements.
Methods: Liver injury pattern, severity and outcomes, potential genetic associations,
and exposure to anabolic steroids by product analysis were analysed in prospectively
enrolled subjects with bodybuilding supplement‐induced liver injury with causality
scores of probable or higher.
Results: Forty‐four males (mean age 33 years) developed liver injury with a median
latency of 73 days. Forty‐one per cent presented with hepatocellular pattern of liver
injury as defined by the R > 5 ([Fold elevation of ALT]  [Fold elevation of Alk
Phos] (mean, range = 6.4, 0.5‐31.4, n = 42) despite all presenting with clinical fea-
tures of cholestatic liver injury (100% with jaundice and 84% with pruritus). Liver
biopsy (59% of subjects) demonstrated a mild hepatitis and profound cholestasis in
most without bile duct injury, loss or fibrosis. Seventy‐one per cent were hospi-
talised, and none died or required liver transplantation. In some, chemical analysis
revealed anabolic steroid controlled substances not listed on the label. No enrich-
ment of genetic variants associated with cholestatic syndromes was found, although
mutations in ABCB11 (present in up to 20%) were significantly different than in eth-
nically matched controls.
Conclusions: Patients with bodybuilding supplements liver injury uniformly pre-
sented with cholestatic injury, which slowly resolved. The ingested products often
contained anabolic steroids not identified on the label, and no enrichment in genetic
variants was found, indicating a need for additional studies.
*The DILIN Investigators are listed in Appendix S1.
The Handling Editor for this article was Professor Stephen Harrison, and it
was accepted for publication after full peer‐review.
Received: 30 November 2018 | First decision: 2 January 2019 | Accepted: 10 February 2019
DOI: 10.1111/apt.15211
Aliment Pharmacol Ther. 2019;49:1195–1204. wileyonlinelibrary.com/journal/apt © 2019 John Wiley & Sons Ltd | 1195
15 (Indiana), 1U01‐DK083027‐09 (TJH/
UPenn), 1U01‐DK082992‐05 (Mayo), 1U01‐
DK083020‐10 (USC). Additional funding is
provided by CTSA grants: UL1 RR025761
(Indiana), UL1 TR000083 (UNC), UL1
RR024986 (Michigan), UL1 RR TR001855
(USC) and in part by the Intramural Research
Program of the NIH, National Cancer
Institute.
1 | INTRODUCTION
Androgenic anabolic steroids are modified androgens or prohor-
mones that promote muscle growth and are used to enhance athletic
performance or improve physique.1,2 Several anabolic steroids have
been approved as therapy of hypogonadism, cachexia, anaemia and
other disorders. However, these products can also cause diverse
liver abnormalities, including severe and prolonged cholestatic liver
injury, peliosis hepatis, hepatic adenoma and even hepatocellular car-
cinoma with prolonged use, albeit in a minority of patients.3–7 These
risks, as well as cardiovascular injury, hyperlipidaemia, and infertility,
along with the development of dependence, have prompted increas-
ing Food and Drug Administration and Drug Enforcement Adminis-
tration (DEA) regulation of anabolic steroids in the United States.
Despite the increased oversight, numerous examples of contamina-
tion of bodybuilding supplements with illegal anabolic steroids have
been reported, demonstrating that these supplements remain an
important source of illicit anabolic steroid exposure.3,8–10
Little is known about the pathophysiological mechanisms of pro-
longed cholestasis associated with anabolic steroids or who is at risk
for developing liver injury. Previous small studies have identified a few
variants associated with genetic cholestatic disorders in those that
develop cholestastic liver injury after using bodybuilding supple-
ments.11,12 Anabolic steroid modifications allowing for oral administra-
tion and those specifically with a C‐17 alkylated modification are
known to be associated with cholestatic liver injury,1 but a detailed
time course of liver injury, histologic evaluation, genetic characterisa-
tion and chemical analysis of supplements in a large cohort is lacking.
The drug‐induced liver injury network (DILIN) has prospectively
enrolled patients with drug or herbal and dietary supplement‐associ-
ated liver injury to characterise their clinical features and to generate a
well‐phenotyped biospecimen repository for future mechanistic and
genetic association studies.13,14 A previous review of the DILIN's
experience with herbal and dietary supplement, which constituted the
second most common class of agents causing drug‐induced liver injury
(DILI), identified supplements advertised to promote bodybuilding as
the largest class within this category.15 Patients consuming bodybuilding
supplements often presented with a distinct clinical phenotype of a
profound cholestatic liver injury in the absence of significant biliary
obstruction. The current report now describes the clinical features,
laboratory findings, histological features and outcomes among 44
consecutive patients enrolled with bodybuilding supplements
induced liver injury in this well‐characterised prospective cohort of
patients. In addition, chemical analysis of the ingested products in
14 subjects and potential genetic associations were conducted in 41
cases, respectively, to explore potential exposure to anabolic steroids
and mechanisms of liver injury.
2 | MATERIALS AND METHODS
2.1 | Recruitment of DILIN prospective study
All patients were enrolled into an ongoing, multicentre prospective
Registry study which had been approved by Institutional Review
Boards at all clinical sites and the data coordinating centre, as well
as by an independent Data and Safety Monitoring Board appointed
by the NIDDK. All subjects (NCT00345930) provided written
informed consent for the collection and analysis of clinical data and
biological specimens for genetic testing.13,14 The DILIN previously
reported its experience with liver injury due to herbal and dietary
supplement between 2004 and March 2013.15 Reassessment of
these original herbal and dietary supplement cases identified 44
attributed to bodybuilding supplements. For the study, liver injury
onset was defined as the first day of documented liver injury after
being exposed to the bodybuilding supplement and meeting one of
the following criteria for inclusion into the study on two successive
blood samples, collected at least 24 h apart: (a) a serum aspartate
aminotransferase (AST) or alanine aminotransferase (ALT) level
greater than five times the upper limit of normal (or five times the
baseline elevated value if known); (b) a serum alkaline phosphatase
(Alk Phos) level that exceeded two times the Upper limit of normal
(ULN; or two times a pretreated abnormal baseline value if known);
or (c) a serum total bilirubin of 2.5 mg/dL or greater or an interna-
tional normalised ratio (INR) greater than 1.5 in combination with
any enzyme elevation. Patients with injury within the past 6 months
were eligible for enrolment into the prospective study. A detailed
review of the patient's medical history and record was performed at
initial enrolment, and narrative generated summarising key clinical
features. Additional laboratory tests and imaging studies were per-
formed to exclude other potential aetiologies. In addition, patients
were screened for hepatitis A, B, C, E, HIV, CMV and EBV infections
and for routine autoantibodies. Patients were asked to return for fol-
low‐up at 6 months, and if evidence of persistent liver injury was
noted at that time, they were asked to return for further follow‐up
at 12 and 24 months.
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The assessment of causality between the liver injury and the
implicated agent was carried out using a standardised process based
upon the pertinent clinical, biochemical, radiological and histologic
findings if available after the 6‐month follow‐up visit.16 DILIN expert
opinion causality scores ranged from 1 (definite: ≥95% likelihood), 2
(highly likely: 75%‐94% likelihood), 3 (probable: 50%‐74% likelihood),
4 (possible 25%‐49% likelihood) to 5 (unlikely: <25% likelihood). The
pattern of liver injury was defined by the R = [ALT/ULN][Alk Phos/
ULN], based on which cases were defined as hepatocellular (R > 5),
cholestatic (R < 2) or mixed (R = 2‐5). The severity of injury was
scored from mild (1), moderate (2), moderate‐hospitalised (3), severe
(4) and fatal (5), if death from liver disease or liver transplantation
occurred within 6 months of the onset.14
2.2 | Liver histopathology
There was no requirement for a liver biopsy for enrolment, but if
performed for routine clinical care, available slides were collected
and sent to a single expert liver histopathologist (DEK) who exam-
ined and scored them for multiple histological features as well for a
global pattern of liver injury.17
2.3 | Anabolic steroid analysis
Chemical analysis of bodybuilding supplements products for botani-
cals, amino acids, vitamins, pharmaceutical agents and 37 different
anabolic steroids were performed using ultra‐high performance liquid
chromatography‐quadrupole time of flight‐mass spectrometry
(UHPLC/QToF‐MS) with modifications in the extraction methodology
(see Data S1).
2.4 | DNA sequencing and genotyping
Genomic DNA samples from 25 subjects with bodybuilding supple-
ments DILI underwent whole genome sequencing (WGS) at Duke
University using Illumina GAIIx or HiSeq 2000 or 2500 sequencers.
An additional 16 cases were genotyped with an exome chip: 10
cases were genotyped with the Illumina HumanExome chip, and six
cases were genotyped with the Illumina Multi‐Ethnic Genotyping
Array (MEGA), which includes the same low‐frequency coding variants
as the HumanExome chip. The genes ABCB11 (BSEP), ABCB4
(MDR3) and ATP8B1 (PFIC 1) were chosen as candidate genes as
they are known to cause progressive familial intrahepatic cholesta-
sis.18 Data were analysed according to standard protocols as
described in the Supplemental Methods.
2.5 | Data collection and statistics
Data from cases were deposited in electronic case report forms
(eCRFs) via the InForm™ (Oracle Health Solutions, CA) and were
downloaded in 2016. Summary statistics were reported as median
with range for continuous data and frequency with percentage for
categorical data using the SAS 9.4 (SAS Institute, Cary, NC) statistical
software.
3 | RESULTS
3.1 | Demographics, clinical features and laboratory
findings
The demographic and clinical features of the 44 patients with liver
injury attributed to bodybuilding supplements enrolled between
2004 and November 2013 are shown in Table 1 and laboratory and
outcome features in Table 2. All patients were adult males with a
median age of 31.5 years (range: 21‐59) with 82% self‐reporting
their race as white or Caucasian, 11% as African‐Americans, 2%
Asian and 5% multiracial or other and 11% identified themselves as
Latino. Twenty‐one per cent reported prior drug allergies and 80%
admitted to drinking alcohol at least once in the past year. Of those
that consumed alcohol, five were heavy drinkers as defined by con-
suming more than three drinks per day.19 There were no significant
TABLE 1 Clinical and demographic features of 44 patients with
suspected anabolic steroid jaundice
Feature
Number
positive
or median
Proportion
or range
Sex (male) 44 100%
Age (yr) 31.5 21‐59
Self‐reported race
White/Caucasian 36 82%
Black/African American 5 11%
Asian‐American 1 2%
Other/Multiracial 2 5%
Weight (kg) (n = 43)a 88.2 50.5‐117.1
BMI (kg/m2) (n = 43)a 26.2 19.9‐37.4
Pre‐existing conditions
Diabetes/endocrine Ds 0 0%
Alcohol use (n = 43)a 35 81%
HCV RNA positive (n = 43)a 3 8%
HIV positive 1 2%
Family history liver disease 1 2%
Bodybuilding supplement latency (mo) 2.5 0.45‐15.5
Signs and symptoms
Jaundice 44 100%
Pruritus 37 84%
Abdominal pain 26 59%
Nausea 27 61%
Rash 11 25%
Fever 7 16%
aData not available on all 44 patients; number given in brackets.
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clinical or laboratory differences in those that were heavy drinkers
(n = 5) compared to the nonheavy alcohol consumers (n = 30). No
one reported any pre‐existing diabetes or chronic medical condition
and only three had hypertension. One patient was HIV positive and
three had established chronic HCV infection. The median time from
the start of the bodybuilding supplement to onset of liver injury was
76 days, 9% occurring within the first 2‐4 weeks and 14% occurring
after 24 weeks, although precise dates of starting and stopping the
supplements were often lacking.
All patients presented with jaundice and most (84%) with pru-
ritus, strongly suggesting cholestatic liver injury. Ninety‐eight per
cent took an oral agent and one used self‐administered intramus-
cular injections of reported testosterone‐3‐propionate, which had
been purchased in Mexico without a prescription. None of the
bodybuilding supplements taken by the patients were prescribed
or supervised by a physician. All of them consumed the supple-
ments to enhance physique or augment muscle mass, often in
combination with an exercise and weight loss programme and
with various nutritional supplements such as whey protein and
creatine.
Table 2 includes results of initial laboratory tests obtained an
average of 96 days after initiating bodybuilding supplements. The
median initial serum ALT value was modestly elevated (169 U/L) with
a wide range (61‐1254 U/L) and over half had ALT levels >3 ULN.
All patients presented with significant jaundice with a median total
serum bilirubin value of 9.8 mg/dL (range, 4.1‐45.7 mg/dL). Despite
the clinical symptoms suggestive of a cholestatic pattern of liver
injury, the initial median Alk Phos value was only 111 U/L (range,
53‐461 U/L), with 70% of subjects having values within the local
normal range. The median calculated R value on presentation was
3.9, only 29% presenting with a cholestatic pattern of liver injury
(R < 2) and 40% presenting with a hepatocellular pattern (R > 5),
despite the prominence of jaundice and pruritus. The elevated R
value was largely due to the normal or minimally elevated levels of
Alk Phos, rather than high ALT values. One or more gamma‐glutamyl
transpeptidase (GGT) levels were available in 39 patients, but only
two at onset, and only two had raised values, with the peak median
GGT of 44.5 U/L, with a range of 13–118. Elevated serum choles-
terol (median of 202 mg/dL: n = 34, range 62‐630) and triglyceride
(median 233 mg/dL: n = 36, range 6.3‐614) levels were also
observed at onset. Twenty per cent of subjects underwent an endo-
scopic retrograde cholangiopancreatography (ERCP) or magnetic res-
onance cholangiopancreatography, and 59% had a liver biopsy as
part of their initial evaluation.
3.2 | Duration of injury and pattern of hepatic
injury
Jaundice was typically prolonged, the median time from onset to
serum bilirubin falling below 2.5 mg/dL being slightly more than
3 months (94 days). Typically, serum aminotransferase levels fell
rapidly during the course of the disease, the peak median ALT value
(189 U/L) being minimally higher than the median value on
TABLE 2 Laboratory features of 44 patients with suspected
anabolic steroid jaundice
Feature
Number positive
or median
Proportion
or range
Initial values at onset
ALT (U/L) 169 61‐1254
AST (U/L) 82 38‐278
Alk Phos (U/L) 111 53‐461
Bilirubin (mg/dL) 9.8 4.1‐45.7
R value
Injury pattern (n = 42)
Cholestatic 12 29%
Mixed 13 31%
Hepatocellular 17 41%
Peak values during course
ALT (U/L) 189 64‐1254
AST (U/L) 128 55‐472
Alk Phos (U/L) 257 83‐625
Bilirubin (mg/dL) 25.8 7.3‐63.0
INR 1.1 0.9‐2.1
Duration of abnormalities
Bilirubin ≥2.5 mg/dLb (n = 36) 94.3 34‐459
Chronic laboratory abnormalities (mo)a
6 (n = 31)c 4 39%c
12 (n = 12) 2 50%d
24 (n = 2) 2 100%d
Other Investigations or interventions
MRCP or ERCP 9 20%
Liver biopsy 22 50%
Corticosteroid therapy (n = 43) 7 16%
Ursodiol therapy at time of
enrollment
21 47%
Creatinine >1.5 mg/dL 6 14%
Causality, severity and outcomes
Severity score
1 (mild, anicteric) 0 0%
2 (moderate, icteric) 10 23%
3 (moderate, hospitalised) 25 57%
4 (severe, organ failure) 9 21%
5 (fatal or liver transplant) 0 0%
Causality scores
Definite 25
Highly likely 19
Probable 0
Data not available on all 44 patients; number given in brackets.
aChronicity defined as any abnormal of serum ALT, total bilirubin or alka-
line phosphatase 6 mo after presentation.
bOnly 36 subjects whose duration can be calculated with observed biliru-
bin level <2.5.
cOnly 16 of the patients came for their 6‐mo follow‐up.
dPercentage of chronic patients at 6 mo followed up at 12 and 24 mo.
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presentation (169 U/L). In contrast, serum Alk Phos levels typically
rose, the peak median value being twice that of the initial value (257
vs 111 U/L). For these reasons, the R value fell rapidly during the
course of the injury to a median of less than 2 (cholestatic) within
2 weeks. Figure 1 illustrates the pattern of serum ALT, Alk Phos and
bilirubin over time after enrollment based on available data. Despite
the marked hyperbilirubinemia, signs of hepatic failure were uncom-
mon with the median peak INR being 1.1 (range from 0.9 to 2.1)
with only 6 greater than 1.5. No patient developed ascites or hepatic
encephalopathy. Several, however, developed renal insufficiency with
serum creatinine levels rising above 1.5 mg/dL in six patients and
above 2.5 mg/dL in 3 (peak values 2.7, 3.2 and 3.3 mg/dL). Peak
serum bilirubin levels in these three patients with renal insufficiency
were all very high (46.7, 46.8 and 50.9 mg/dL), and all patients had
resolution of the renal insufficiency with recovery from the liver
injury.
3.3 | Liver histology
Twenty‐six patients underwent liver biopsies, of which 22 were
available for independent review by the DILIN hepatic pathologist
(DEK), who was masked to all clinical information. The median time
from DILI onset to the liver biopsy was 15 days (range 1‐68). The
most common histologic pattern was a mixed hepatocellular and
cholestatic injury (77%), and only 4 (18%) had acute cholestasis.
Hepatocellular injury was typically spotty and mild, and no patient
had bridging or confluent necrosis. Some degree of cholestasis was
found in all biopsies but bile duct injury was found in only 14% with-
out any bile duct loss. Steatosis was uncommon (10%), and no
patient had more than mild portal fibrosis. One case showed micro-
scopic evidence suggestive of peliosis hepatis and nodular regenera-
tion. Figure 2 illustrates some common histological features
identified.
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F IGURE 1 Median total bilirubin (mg/dL) (μmol) or Alk Phos (AKP) and ALT activity in U/L plotted over time in weeks after presentation.
The lines connect the median values over time for each serum test. The numbers of subjects at different time period for ALT are as follows
(with about ±1 for others): 44 at onset (day 0); 36 at week 1; 31 at week 2; 35 for week 3‐4; 29 for week 5‐6; 22 for week 7‐8; 23 for week
8‐12; 36 for >12 weeks. Mean values are depicted as symbols inside the box with the top and bottom of the box representing the 25 and 75
percentiles, respectively
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3.4 | Causality assessment, severity of liver injury
and chronicity
Of the 44 cases, 25 were scored as definite and 19 as highly likely,
while none were considered probable, reflecting the consistent phe-
notype and demographic characteristics of those with bodybuilding
supplement‐induced liver injury. The mean severity of illness was 3
with a range of 2‐4 where 2 represented the presence of jaundice, 3
as jaundice with hospitalisation and 4 as severe injury with evidence
of hepatic or another organ failure.13 Thirty‐one subjects (71%) were
hospitalised for the acute liver injury (severity 3), but none died or
underwent liver transplantation (severity 5) as was recently reported
in another cohort.20
Of the 44 subjects with bodybuilding supplement‐induced liver
injury, only 16 (36%) returned for their scheduled 6‐month follow‐up
visit, of whom half had ALT greater than ULN. Twelve subjects
returned at 12 months with 2 having ALT greater than ULN. In all
cases, the serum enzyme elevations were mild and no patient was
persistently jaundiced or symptomatic.
3.5 | Chemical analysis of bodybuilding supplement
components
Starting in 2009, the available incriminated herbal and dietary sup-
plement products were submitted to a centralised repository, where
they were catalogued and stored for future analysis. Thirty‐three
bodybuilding products were collected from 14 patients (subjects
commonly consumed more than one bodybuilding supplement at a
time) and were screened for anabolic steroids and related com-
pounds. At least, one anabolic steroid was identified in 14
bodybuilding supplements provided by nine of the 14 patients but
not in the 19 supplements from the remaining five. The labels often
did not accurately reflect the chemical structure of the components
as 17 of the 21 bodybuilding supplements contained anabolic ster-
oids that were different from those listed on the label, and 12 of the
steroids listed on the labels were not identified by chemical analysis.
Only six anabolic steroids listed on the label were confirmed by
chemical analysis. The anabolic steroids that were most frequently
encountered were methyldrostanolone (55%) followed by tetrahy-
drocorticosterone (44%), 4‐androstenedione (33%) and DHEA (33%).
Listed in Table S1 are the case numbers, names of the primary
bodybuilding supplements suspected to be the cause of the liver
injury, whether the product label listed an anabolic steroid as an
ingredient and, in 14 samples (nine subjects), whether an anabolic
steroid was identified analytically. In some cases, none of the
products contained detectable anabolic steroids or the product
believed to contain one was not available for testing. Thirteen of the
steroids identified were DEA controlled substances.
3.6 | Genetic association studies
Twenty‐five patients underwent WGS. Among the 22 patients of
European‐American ethnicity who underwent WGS, four were
heterozygous (carriers) for rare missense variants in candidate genes
previously reported to be associated with progressive familial intra-
hepatic cholestasis (PFIC) disorders: ATP8B1 (PFIC1), ABCB11 (BSEP)
(PFIC2) or ABCB4 (MDR3) (PFIC3) (Table 3). Three additional
patients, identified by exomic chip analysis, had variants in ATP8B1:
two carried the D70N missense variant associated with PFIC/BRIC1
cases, which also showed some evidence of enrichment in our cases
(case MAF (Minor allele frequency) 2.9% vs 0.4% in gnomAD con-
trols, P = 0.04) and one had the N45T missense variant, which has a
frequency of 0.75% in European‐American ancestry controls. Finally,
a single subject had a rare variant in ABCB4, namely R590Q, which
(A)
(C)
(B)
(D)
F IGURE 2 Histological findings in
anabolic steroid DILI. Anabolic androgenic
steroid liver injury is classically associated
with bland cholestasis. There is canalicular
and hepatocellular cholestasis with little or
no lobular inflammation (A), and portal
areas have a normal appearance without
inflammation (B). (H&E, 600× and 400×,
respectively). Most of the cases in this
report had mild degree of inflammation.
Multiple small foci of lobular inflammation
(arrowheads) are seen along with
canalicular cholestasis (arrows) (C). The
portal areas of this case also show
inflammation (D)
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has a frequency of 0.68% in controls. When including the 12
patients of European‐American ethnicity who had exome chip data
available, three additional carriers of rare missense variants were
identified, all in the ABCB11 gene. Two carried the E297G variant
previously associated with PFIC2, which has a frequency of 0.04% in
European ancestry controls, and one carried the I206V variant,
which has a frequency of 0.002% in controls. E297G variant in
ABCB11 is extremely rare in population controls of European ances-
try (MAF 0.04%) but was found in two of the 34 European ancestry
cases (MAF 2.9%; Fisher's exact test P = 0.0004) and demonstrated
a significant difference between our patients and the European
ancestry controls in gnomAD.21 In addition, one of the five African‐
American patients carried the variant V1112I in ABCB11, which has
a frequency of 0.02% in African ancestry controls. The non‐Euro-
pean cases did not have any rare functional variants in any of these
three genes identified by exome chip analysis.
To asses for overall enrichment of rare functional variants in
these three genes in cases as compared to population controls, data
from the gnomAD database were used to conservatively estimate
that 12.3% of European ancestry population controls have a coding
variant with a MAF below 1% in at least one of these genes, as
compared to 20.6% in our cases. As 12 of our European ancestry
cases were genotyped only for low‐frequency coding variants by
chip analysis (for included variants, see Table S2), some very rare
variants may have been missed, but the frequency overall of cases
with rare missense mutations in at least one of these genes was sim-
ilar between our WGS cases (18%) and our exome chip cases (25%).
When variants were removed as predicted by PolyPhen‐2 HumDiv22
to be benign, only 8.1% of the population controls were predicted to
be carriers, whereas 17.6% of cases remained carriers. Almost 9% of
our European ancestry cases had rare missense variants predicted to
be probably damaging in ATP8B1 as compared to 4.3% of controls
(8.9% vs 5.6% when including benign variants), 5.8% in ABCB11
compared to 1.0% in controls (8.9% vs 3.3% with benign) and 2.9%
in ABCB4 compared to 2.7% in controls (2.9% vs 3.4% with benign).
In the bodybuilding supplement cases, there was some clustering of
variants in specific regions of ABCB11 gene as compared to controls.
The two ABCB11 variants found in European ancestry cases, one of
which was seen in two cases, were both in the ABC transmembrane
domain. In contrast, no more than 0.4% of European ancestry gno-
mAD controls have rare missense variants in this region. Similarly,
the two ATP8B1 variants found in our cases, one of which was seen
in two cases, were within 25 amino acids of each other; in contrast,
no more than 2.5% of controls have rare missense variants within
25 amino acids of either of these variants (Figure S1). These findings
suggest that genetic variants, particularly in ABCB11, might predis-
pose to bodybuilding supplement‐associated cholestatic injury in
some individuals, as has been postulated for cholestasis due to phar-
maceutical agents.23
4 | DISCUSSION
4.1 | Clinical features of cholestatic liver injury due
to anabolic steroids
The clinical features of cholestatic liver injury in these 44 patients
are consistent with prior observations of those exposed to anabolic
steroids that include C‐17 alpha alkylation.3,24 The next largest case
series describes 25 cases of anabolic steroid‐associated liver injury,
predominately attributed to stanozolol.25 Other clinical descriptions
consist of small case series with predominately oral agents. How-
ever, our study includes prospective data providing more detailed
clinical course description and extensive genetic analysis in a major-
ity of cases along with chemical analysis of bodybuilding supple-
ments ingested, the latter carrying important regulatory implications.
All of our cases arose in men, typically young with few other
medical problems. The vast majority admitted to drinking some alco-
hol in the past year, and we previously reported that heavy alcohol
consumption was associated with exposure to bodybuilding supple-
ments.19 As compared to the subjects with bodybuilding supple-
ment‐associated DILI, the entire cohort of subjects enrolled into the
DILIN with causality score of probably or greater, reported that only
50% had some alcohol consumption in the past year and of those
that completed the alcohol survey, less than 23% were heavy
drinkers as previously defined.19 Subjects with bodybuilding
TABLE 3 Rare functional variants identified in selected patients
Subject
Genetic
ancestry
Genetic
dataset Gene
Variant (amino
acid position) Variant (chromosomal position)
gnomad
MAF21,a (%)
Polyphen Humdiv
Prediction22
5 Eur Chip ABCB11 E297G 2‐169847329‐T‐C 0.04 Probably damaging
7 Eur Chip ABCB11 I206V 2‐169850388‐T‐C 0.00 Benign
11 Eur WGS ATP8B1 D70N 18‐55373793‐C‐T 0.44 Probably damaging
13 Eur WGS ATP8B1 N45T 18‐55398906‐T‐G 0.75 Possibly damaging
18 Eur WGS ABCB4 R590Q 7‐87060844‐C‐T 0.68 Probably damaging
30 Eur WGS ATP8B1 D70N 18‐55373793‐C‐T 0.44 Probably damaging
39 Eur Chip ABCB11 E297G 2‐169847329‐T‐C 0.04 Probably damaging
41 AA WGS ABCB11 V1112I 2‐169787252‐C‐T 0.02 Probably damaging
Eur indicates European, AA indicates African American; Chip indicates Illumina HumanExome chip, WGS indicates whole genome sequencing; aMAF is
reported for non‐Finnish Europeans for all cases except for the variant found in an African American patient, where the MAF reported is for Africans.
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supplement‐associated DILI commonly presented with pruritus and
reported weight loss during their cholestatic period. The rapid reduc-
tion of ALT followed by increasing values of the total serum bilirubin
and Alk Phos as the injury progressed suggests that hepatocellular
injury is an early event in bodybuilding supplement‐induced liver
injury despite the cholestatic clinical presentation. Transient eleva-
tions in aminotransferase levels have been reported during acute bil-
iary obstruction due to stones or as the initial presentation of
intrahepatic cholestasis of pregnancy.26,27 There are also other case
reports of elevation of the ALT and increased R value in anabolic
steroid‐associated liver injury.25,28 In addition, GGT levels, when
obtained, were rarely elevated for unclear reason. Thus, the present-
ing clinical features of anabolic steroid‐induced cholestasis were
quite distinct leading to the high degree of certainty in their causal-
ity scores. In addition to the clinical presentation, exposure to ana-
bolic steroids can also be confirmed by either the chemical detection
of the anabolic steroid, typically in the urine or offending drug in the
serum such as C‐19 aromatase inhibitors as well as the physiological
response to exogenously consumed anabolic steroid. These studies
include the following: decrease in Follicle‐stimulating hormone and
Luteinizing hormone serum levels, changes in the epi‐testosterone to
testosterone ratio or in the C13/C12 ratio of androgenic steroids in
the urine.29,30
With regard to renal insufficiency (as defined by serum creatinine
>1.5 mg/dL), only six patients were affected and of these, only three
had creatinine persistently elevated above 2.5 mg/dL. The mecha-
nism for renal injury during severe and prolonged cholestasis is
unknown, but the anabolic steroid methasteron has been previously
reported to be associated with renal injury, suggesting that renal
injury may be associated with a specific chemical structure of the
anabolic steroid.31 Alternatively, elevated serum bile salts have also
been implicated in causing renal injury.32 Fortunately, none of the
patients died or required liver transplantation. However, 16% of the
patients were treated with a trial of corticosteroids, with little or no
apparent clinical response, although this was not formally assessed.
In addition, almost half were enrolled on Ursodiol therapy, presum-
ably for cholestatic symptoms. Follow‐up was difficult with these
patients as only 36% returned for a 6‐month follow‐up, a rate far
lower than the average patient enrolled in DILIN (80%), probably
reflecting the background good health of these patients and the illicit
nature of the bodybuilding supplement use. None developed chronic
cholestatic liver injury, vanishing bile duct syndrome33 or liver failure
requiring liver transplantation. There was eventual resolution of all
liver tests in those that were followed for greater than 6 months.
4.2 | Liver biopsy findings
All liver biopsies had histological features of profound intrahepatic
cholestasis, without evidence of duct injury or loss. A mild hepatitis
was noted without fibrosis, as has been previously reported.28 The
liver histology features noted close to the time of elevated serum
aminotransferases were not significantly different from those seen
when the R < 5, although there was a trend to an increased
presence of hepatocyte apoptosis in the former. As none of the
biopsies revealed alternative diagnoses, a liver biopsy may not be
necessary when the distinct clinical presentation is evident in a
young male and exposure history is consistent.
4.3 | Genetic analysis
The prolonged cholestasis with a normal GGT level, when tested, is
clinically reminiscent of patients who present with BRIC due to
genetic variants in ATP8B1, the P type ATPase responsible for
PFIC1 and BRIC‐1, or ABCB11, the bile salt export protein responsi-
ble for PFIC2 or BRIC2. Prior genetic analysis of individuals with
anabolic steroid‐associated cholestatic liver injury with normal GGT
identified heterozygous mutations in ABCB11 and 2 bp deletion in
exon 1 of PXR.11,12 Thus, a concerted effort was made to identify
genetic mutations using WGS and chip‐based discovery. The major-
ity of patients with cholestasis due to anabolic steroids do not have
causal mutations in the genes ATP8B1, ABCB11 (BSEP) or ABCB4
(MDR3). Of note, more variants were found in the first ABC mem-
brane region of ABCB11 and near the N terminus of ATP8B1 as
compared to controls (Figure S1). This trend will require confirma-
tion. There were some limitations as 16 patients were genotyped
with an exome chip, in which case rare variants may not be identi-
fied. For example, two of the variants found in genome sequencing
were not evaluated on the exome chip. Because 12% of controls
had similar variants in these genes, the proportion of cholestatic
cases genetically explained is likely to be far lower than the maxi-
mum estimate. Therefore, mutations in these three candidate genes
can only account for a maximum of 20% of our cases. As only 20%
at most had genetic variants in genes responsible for rare genetic
cholestatic syndrome liver injury may be due to unknown hepatic
transporters either at the canalicular or sinusoidal domain of hepato-
cytes, or variants in other genes.34 Other possible mechanism may
include secondary metabolic effects of anabolic steroids, such as
physical chemical changes in membrane fluidity due to modification
of the lipid composition at the canalicular domain or a direct physical
chemical interaction of the anabolic steroids on membrane or biliary
transporters’ function.
4.4 | Chemical analysis of bodybuilding
supplements
As previously reported, bodybuilding supplement product labels
correlated poorly with the chemical analysis, and the steroids spe-
cies that were found were often not on the label.35 The presence
of anabolic steroids in bodybuilding supplement samples, which are
currently listed as controlled substances (https://www.deadiversion.
usdoj.gov/21cfr/cfr/1300/1300_01.htm), illustrates that these DEA
controlled steroids are easily available for purchase. Although ana-
bolic steroids were not identified in samples from five patients, not
all bodybuilding supplement samples were available for analysis. In
addition, the common phenotypic presentation of these patients
without anabolic steroids detected in these supplements strongly
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suggests exposure. Our data are particularly pertinent in the light
of the increasing use of anabolic steroids in the adolescent popula-
tion. A recent survey revealed that up to 1% of adolescent males
and 0.1% of adolescent females have been exposed to anabolic
steroids in high school with an estimated prevalence of use by 2.9‐
4 million Americans.9 Our chemical analysis confirmed identification
of controlled steroids, and there was a poor correlation between
label and actual content in bodybuilding supplements. These data
along with others35 suggest that greater regulatory oversight is
required to protect the general public.
Strengths of our study include the prospective enrollment of
consecutive cases, high causality scores and extensive phenotyping
including liver biopsies in over 50% of the cases. Available
bodybuilding supplement samples were comprehensively analysed,
and the chemical structure of the anabolic steroid identified in the
vast majority. In this same cohort, genetic variants were sought using
either WGS or chip‐based discovery, which included known variants
in PFIC genes. Weaknesses in our study were the retrieval of
bodybuilding supplement agents in only a third of the subjects,
inability to demonstrate a clear dose response to liver injury and
inadequate follow‐up due to poor subject compliance.
In conclusion, patients with liver injury due to bodybuilding sup-
plements presented with a uniform and distinctive pattern of marked
cholestatic liver injury with pruritus, that was often intractable, pro-
longed and accompanied by disability and weight loss. Liver biopsy
failed to identify another cause suggesting that the clinical diagnosis
of severe cholestasis with minimal elevation of liver tests may be
sufficient to make the diagnosis. As our patient population was pre-
dominately young males, bodybuilding supplement use with likely
anabolic steroid exposure should be strongly considered in the
appropriate patient population who present with new onset jaundice
together with mild elevations in the serum aminotransferase levels.
This may be confirmed by direct testing for the steroid or the physi-
ological consequences of exposure to anabolic androgens as
described.
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